Actively Recruiting
Reversal of Atrial Substrate to Prevent Atrial Fibrillation Cohort Study
Led by Ratika Parkash · Updated on 2025-12-02
198
Participants Needed
7
Research Sites
147 weeks
Total Duration
On this page
Sponsors
R
Ratika Parkash
Lead Sponsor
N
Nova Scotia Health Research Fund
Collaborating Sponsor
AI-Summary
What this Trial Is About
Atrial fibrillation (AF) is a major health problem, with a prevalence of 0.4-1% of the population. It results in high healthcare costs and significant morbidity, especially for patients with severe symptoms. The RASTA-AF randomized control trial (RCT) is designed to answer the following question: does vigorous treatment of AF with aggressive risk factor management plus catheter ablation reduce AF-related outcomes as compared to catheter ablation plus usual care in patients with symptomatic AF and risk factors that promote AF. This study is a multicenter, prospective cohort study that will enrol patients who decline participation in the RASTA-AF RCT but agree to be followed in a registry. The objective of RASTA-Cohort is to determine whether patients who decline participation in the RASTA-AF RCT have different clinical characteristics and quality of life than patients who accept participation in the study, and whether they suffer from worse AF-related outcomes than patients in the RCT.
CONDITIONS
Official Title
Reversal of Atrial Substrate to Prevent Atrial Fibrillation Cohort Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Symptomatic atrial fibrillation with a CCS-SAF score of 2 or higher
- Paroxysmal or persistent atrial fibrillation despite rate control
- Desire for catheter ablation
- Body mass index (BMI) of 30 or higher, or at least two of the following: BMI over 27, blood pressure over 140/90 mmHg or history of hypertension, diabetes, heart failure (prior admission or ejection fraction below 40%), age 65 years or older, prior stroke or transient ischemic attack, current smoker, or excessive alcohol use (women: 10+ drinks/week or more than 2 drinks/day; men: 15+ drinks/week or more than 3 drinks/day)
- Declined or were not approached for participation in the main study
- Received catheter ablation for atrial fibrillation between November 1, 2019 and December 31, 2025
You will not qualify if you...
- Permanent atrial fibrillation lasting more than 3 years
- Prior catheter ablation for atrial fibrillation
- New York Heart Association Class IV heart failure
- Participation in a cardiac rehabilitation program within the last year
- Currently performing more than 150 minutes per week of moderate to vigorous exercise
- Unable to exercise
- Unable to give informed consent
- Other non-cardiovascular medical condition likely to limit survival to less than 1 year
- Younger than 18 years old
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Foothills Hospital
Calgary, Alberta, Canada
Actively Recruiting
2
QEIIHSC
Halifax, Nova Scotia, Canada, B3H 3A7
Actively Recruiting
3
London Health Sciences Centre
London, Ontario, Canada
Actively Recruiting
4
University of Ottawa Heart Institute
Ottawa, Ontario, Canada
Actively Recruiting
5
Sunnybrook Hospital
Toronto, Ontario, Canada
Actively Recruiting
6
Montreal Heart Institute
Montreal, Quebec, Canada
Actively Recruiting
7
Regina General Hospital
Regina, Saskatchewan, Canada
Actively Recruiting
Research Team
L
Laura Hamilton, BSC, MAHSR
CONTACT
K
Karen Giddens
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here